Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. / Vilsbøll, Tina.

I: Expert Opinion on Investigational Drugs, Bind 16, Nr. 2, 01.02.2007, s. 231-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Vilsbøll, T 2007, 'Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus', Expert Opinion on Investigational Drugs, bind 16, nr. 2, s. 231-7. https://doi.org/10.1517/13543784.16.2.231

APA

Vilsbøll, T. (2007). Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 16(2), 231-7. https://doi.org/10.1517/13543784.16.2.231

Vancouver

Vilsbøll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opinion on Investigational Drugs. 2007 feb. 1;16(2):231-7. https://doi.org/10.1517/13543784.16.2.231

Author

Vilsbøll, Tina. / Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. I: Expert Opinion on Investigational Drugs. 2007 ; Bind 16, Nr. 2. s. 231-7.

Bibtex

@article{233707c53fb941b9b98cdad64723343b,
title = "Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus",
abstract = "The incretin hormones are intestinal peptides that enhance insulin secretion following ingestion of nutrients. Liraglutide is a glucagon-like peptide-1 receptor analogue, which is obtained by derivatising glucagon-like peptide-1 with a fatty acid, providing a compound with pharmacokinetic properties that are suitable for once-daily dosing. Liraglutide has demonstrated lasting improvement of HbA(1c )levels, weight reduction and improved beta-cell function in patients with Type 2 diabetes mellitus. Liraglutide is well tolerated; the adverse events that are most frequently reported being transient nausea and diarrhoea. This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development.",
author = "Tina Vilsb{\o}ll",
year = "2007",
month = feb,
day = "1",
doi = "http://dx.doi.org/10.1517/13543784.16.2.231",
language = "English",
volume = "16",
pages = "231--7",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

AU - Vilsbøll, Tina

PY - 2007/2/1

Y1 - 2007/2/1

N2 - The incretin hormones are intestinal peptides that enhance insulin secretion following ingestion of nutrients. Liraglutide is a glucagon-like peptide-1 receptor analogue, which is obtained by derivatising glucagon-like peptide-1 with a fatty acid, providing a compound with pharmacokinetic properties that are suitable for once-daily dosing. Liraglutide has demonstrated lasting improvement of HbA(1c )levels, weight reduction and improved beta-cell function in patients with Type 2 diabetes mellitus. Liraglutide is well tolerated; the adverse events that are most frequently reported being transient nausea and diarrhoea. This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development.

AB - The incretin hormones are intestinal peptides that enhance insulin secretion following ingestion of nutrients. Liraglutide is a glucagon-like peptide-1 receptor analogue, which is obtained by derivatising glucagon-like peptide-1 with a fatty acid, providing a compound with pharmacokinetic properties that are suitable for once-daily dosing. Liraglutide has demonstrated lasting improvement of HbA(1c )levels, weight reduction and improved beta-cell function in patients with Type 2 diabetes mellitus. Liraglutide is well tolerated; the adverse events that are most frequently reported being transient nausea and diarrhoea. This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development.

U2 - http://dx.doi.org/10.1517/13543784.16.2.231

DO - http://dx.doi.org/10.1517/13543784.16.2.231

M3 - Journal article

VL - 16

SP - 231

EP - 237

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 2

ER -

ID: 40221748